logo-loader
RNS
viewGlaxoSmithKline PLC

GlaxoSmithKline PLC - Director/PDMR Shareholding

RNS Number : 5880Z
GlaxoSmithKline PLC
20 May 2019
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

 

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares following the exercise of options granted on 29 October 2015 at the option price of £10.13 per Ordinary Share under the Company's ShareSave Plan. 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£10.13

533

 

 

d)

Aggregated information

 

 

Aggregated volume Price

n/a (single transaction)

 

e)

Date of the transaction

2019-05-17

f)

Place of the transaction

 

London Stock Exchange (XLON)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHLBLFLKEFZBBX

Quick facts: GlaxoSmithKline PLC

Price: 1625.8

Market: LSE
Market Cap: £81.57 billion
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE